Eletriptan Hydrobromide for Spinal Cord Injury Treatment
Summary
The USPTO issued Patent US12605362B2 to TECHNOPHAGE, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA, S.A. on April 21, 2026, covering the use of Eletriptan Hydrobromide for treating spinal cord injury and improving locomotive function. The patent (CPC: A61K 31/4045; 11 claims) was based on discovery work using a larval zebrafish drug discovery platform and confirmation in a rodent contusion model. This is the first grant in Application No. 17794595, filed December 21, 2020.
“Taking advantage of a larval zebrafish drug discovery platform it is identified herein that Eletriptan Hbr has locomotor recovery properties in a pro-regenerative model and it has been confirmed to have conservative effect on a rodent (pro-fibrotic) contusion model.”
About this source
GovPing monitors USPTO Patent Grants - Pharma (A61K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 26 changes logged to date.
What changed
The USPTO granted Patent US12605362B2 for a new therapeutic use of Eletriptan Hydrobromide — previously indicated for migraine — extending its application to spinal cord injury treatment and locomotor function recovery. The invention was identified through a larval zebrafish drug discovery platform and validated in a rodent pro-fibrotic contusion model. The patent contains 11 claims under CPC classification A61K 31/4045.
Affected parties in the biotechnology and pharmaceutical sectors should note that this patent creates a new intellectual property position for Eletriptan Hbr in the spinal cord injury indication. Generic manufacturers, competing drug developers, and potential licensees should review freedom-to-operate implications. Research institutions working in serotonin-receptor-mediated neuroprotection may also need to assess overlapping IP claims.
Archived snapshot
Apr 25, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Eletriptan hydrobromide for treatment of spinal cord injury and improvement of locomotor function
Grant US12605362B2 Kind: B2 Apr 21, 2026
Assignee
TECHNOPHAGE, INVESTIGAÇÄO E DESENVOLVIMENTO EM BIOTECNOLOGIA, S.A.
Inventors
Diana Sofia Chapela Duarte Pires, Sofia Marisa Volker Côrte-Real, Maria Leonor Tavares Saúde, Isaura Vanessa Antunes Martins, Sara Cristina Mauricio De Sousa
Abstract
The present invention discloses the use of Eletriptan Hydrobromide in the treatment of spinal cord injury and improvement of the locomotive function. Despite the major efforts done in attempting to improve the limited recovery upon injury, only a multi-target combinatorial therapeutic approach should be effective for the complexity of spinal cord injury nature. Taking advantage of a larval zebrafish drug discovery platform it is identified herein that Eletriptan Hbr has locomotor recovery properties in a pro-regenerative model and it has been confirmed to have conservative effect on a rodent (pro-fibrotic) contusion model. This approach allowed to identify a promising new therapeutic indication for Eletriptan Hbr, which associated with a combinatorial therapeutic strategy and innovative engineering approaches, shows great potential for spinal cord injury recovery.
CPC Classifications
A61K 31/4045
Filing Date
2020-12-21
Application No.
17794595
Claims
11
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Grants - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.